Abstract
In Europe a process of harmonisation of standards and regulations on genetic testing has started. Public discussion and consultation are recommended, but it is not clear in every European country how the decision making process as regards the further introduction of genetic testing services should be formed. In this paper the usefulness and importance of an overseeing body for genetic screening and testing is founded on four lines of reasoning: (1) analysis of the role of value judgments in the use of the concept of (genetic) abnormality; (2) a balancing of potential benefits for all parties involved; (3) a balancing of potential disadvantages, and (4) the greater availability of commercial genetic tests in the future. It is further argued that such an overseeing body has advantages for all the interested parties.
Key Words: Genetic testing • commercialisation • normality • overseeing body
Full Text
The Full Text of this article is available as a PDF (101.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Hoedemaekers R., ten Have H. Geneticization: the Cyprus paradigm. J Med Philos. 1998 Jun;23(3):274–287. doi: 10.1076/jmep.23.3.274.2585. [DOI] [PubMed] [Google Scholar]
- Hoedemaekers R., ten Have H. The concept of abnormality in medical genetics. Theor Med Bioeth. 1999 Dec;20(6):537–561. doi: 10.1023/a:1009949222667. [DOI] [PubMed] [Google Scholar]
- Post S. G., Whitehouse P. J., Binstock R. H., Bird T. D., Eckert S. K., Farrer L. A., Fleck L. M., Gaines A. D., Juengst E. T., Karlinsky H. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA. 1997 Mar 12;277(10):832–836. doi: 10.1001/jama.277.10.832. [DOI] [PubMed] [Google Scholar]
- Wilfond B. S., Nolan K. National policy development for the clinical application of genetic diagnostic technologies. Lessons from cystic fibrosis. JAMA. 1993 Dec 22;270(24):2948–2954. [PubMed] [Google Scholar]